Navigation Links
DIA and National Pharmaceutical Council Will Host Two-Day Conference on Comparative Effectiveness Research

WASHINGTON, Feb. 28, 2012 /PRNewswire/ -- DIA and the National Pharmaceutical Council (NPC) will co-host the Comparative Effectiveness: A Real-World User's Guide Conference on March 14-15 at the Renaissance Washington Hotel in Washington, D.C. The conference will focus on the continued push for increased levels of evidence of comparative effectiveness research (CER) applied within health technology assessments, research planning and drug development.

Three distinguished CER researchers -- Bryan R. Luce, Senior Vice President, Science Policy, United BioSource Corp., Sean Tunis, Founder and Director, Center for Medical Technology Policy, and Brian Sweet, Executive Director, Healthcare Alliances, AstraZeneca -- will announce the first set of guiding principles developed for conducting CER studies. They also will discuss the practical application of the principles, and debate the effects the principles may have on various constituency groups, including patients, payers, and pharmaceutical industry manufacturers.

More than $1 billion dollars has been invested in comparative effectiveness research, and funding is only expected to grow in coming years. CER is designed to inform health care decisions by providing evidence on the effectiveness, benefits and harms of different treatment options. The evidence is generated from research studies that compare drugs, medical devices, tests, surgeries or ways to deliver health care. As CER becomes a standard by which patient access to new products and services is granted, the need to develop guiding principles to help yield desirable results is heightened.

The conference and sessions are timely as the complexities involved in comparative effectiveness research continue to demand principles and guidelines that can help govern and frame the entire CER enterprise. In addition, the recent creation of the Patient-Centered Outcomes Research Institute (PCORI), as well as new standards for evidence evaluation by leading payers, have made understanding the applications vitally important.

DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology and medical devices. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India and Beijing, China.

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL International to Present at Cowen Healthcare Conference and Raymond James Investors Conference
2. Osseon® Announces International Distribution Agreement with Aesculap
3. NMEDA Introduces National Mobility Awareness Month for Seniors, Veterans and People with Disabilities
4. CVS Caremarks MinuteClinic to Deploy Allscripts EHR Nationally
5. SurgLine International, Inc. Update to Shareholders on Revenue Pipeline and Organizational Changes
6. National Coalition Holds Prescription Drug Take-back Day in Palm Springs Ahead of Pain Medicine Scientific Meeting
7. Access Pharmaceuticals MuGard Added to Nationally Ranked Childrens Hospital of Colorado Pharmacy Formulary
8. To Take a Glance Cutting Edge Medicine Equipment! The 28th International Medical & Hospital Equipment Show
9. National Data Center Hosting Provider, CoreLink Data Centers, to Present at HIMSS 2012
10. Natural Alternatives International, Inc. Files Patent Infringement Claim Against DNP International Co., Inc.
11. Nationally Recognized Glenveigh Medical Announces Orphan Drug Designation for Treatment for Severe Preeclampsia and Eclampsia
Post Your Comments:
(Date:11/27/2015)... 2015 ... "2016 Global Tumor Marker Testing Market: ... Sales Segment Forecasts, Innovative Technologies, Instrumentation Review, ... their offering. --> ) ... "2016 Global Tumor Marker Testing Market: Supplier ...
(Date:11/26/2015)... 2015 --> ... combineert immunotherapie met Bremachlorin-photodynamische therapie voor de ... ) --> ... ) Uit een ... (LUMC) blijkt dat ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... An inventor, ... to dispense prescription medications at home, so he invented the patent-pending ELECTRONIC M.D. ... dispense prescription medications. In doing so, it could help to prevent potential overdose ...
(Date:11/27/2015)... ... ... No.1 Herpes-only dating community in the world, revealed that over 50% of its members are ... people under the age of 50 – or 67% of the population - are infected ... HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping ... platform for mental health and wellness consultation, has collaborated with a leading web-based ... the knowledge gap experienced by parents and bring advice from parenting experts within ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... contact center software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term ... fully supported Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug ... need to integrate dose form selection in early phase drug development. The first ... supporting and bringing together the UK’s emerging life sciences companies, corporate partners, and ...
Breaking Medicine News(10 mins):